No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Cabergoline (Parkinson's disease)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabergoline is extensively metabolized by the liver predominantly via hydrolysis (non-CYP mediated metabolism).
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking